Do the Results of the New Trials Change the Standard Treatment of Metastatic Renal Cell Cancer?

Publisher： Karger

E-ISSN： 2296-5262|30|5|260-264

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.5, 2007-04, pp. : 260-264

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 122-131

Karger

Access to resources Recommend Favorite

Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 288-292

John Wiley & Sons Inc

Access to resources Recommend Favorite

Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients

By  

Urologia Internationalis, Vol. 64, Iss. 1, 2000-04 ,pp. : 3-8

Karger

Access to resources Recommend Favorite

Treatment of Metastatic Renal Cell Carcinoma: How Reliable are Small Non-Randomised Clinical Trials? Concerning Mross et al.: Onkologie 1999;22:412–415.

By  

Oncology Research and Treatment, Vol. 22, Iss. 6, 2000-01 ,pp. : 520-520

Karger

Access to resources Recommend Favorite

The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer

By  

Urologia Internationalis, Vol. 86, Iss. 1, 2010-10 ,pp. : 53-59

Karger

Access to resources Recommend Favorite